Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 24991 | 246 | 31.5 | 81% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | LINOMIDE | Author keyword | 99 | 80% | 25% | 61 |
| 2 | ROQUINIMEX | Author keyword | 15 | 82% | 4% | 9 |
| 3 | LAQUINIMOD | Author keyword | 13 | 47% | 9% | 21 |
| 4 | TASQUINIMOD | Author keyword | 10 | 63% | 4% | 10 |
| 5 | QUINOLINE 3 CARBOXAMIDE | Author keyword | 6 | 71% | 2% | 5 |
| 6 | GLOBAL INNOVAT RD | Address | 5 | 63% | 2% | 5 |
| 7 | ABR 215050 | Author keyword | 3 | 100% | 1% | 3 |
| 8 | ABR 215062 | Author keyword | 2 | 67% | 1% | 2 |
| 9 | LUND | Address | 2 | 22% | 2% | 6 |
| 10 | SPINAL CORD MOTONEURONS | Author keyword | 1 | 100% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | LINOMIDE | 99 | 80% | 25% | 61 | Search LINOMIDE | Search LINOMIDE |
| 2 | ROQUINIMEX | 15 | 82% | 4% | 9 | Search ROQUINIMEX | Search ROQUINIMEX |
| 3 | LAQUINIMOD | 13 | 47% | 9% | 21 | Search LAQUINIMOD | Search LAQUINIMOD |
| 4 | TASQUINIMOD | 10 | 63% | 4% | 10 | Search TASQUINIMOD | Search TASQUINIMOD |
| 5 | QUINOLINE 3 CARBOXAMIDE | 6 | 71% | 2% | 5 | Search QUINOLINE+3+CARBOXAMIDE | Search QUINOLINE+3+CARBOXAMIDE |
| 6 | ABR 215050 | 3 | 100% | 1% | 3 | Search ABR+215050 | Search ABR+215050 |
| 7 | ABR 215062 | 2 | 67% | 1% | 2 | Search ABR+215062 | Search ABR+215062 |
| 8 | SPINAL CORD MOTONEURONS | 1 | 100% | 1% | 2 | Search SPINAL+CORD+MOTONEURONS | Search SPINAL+CORD+MOTONEURONS |
| 9 | INCURRED SAMPLE STABILITY | 1 | 40% | 1% | 2 | Search INCURRED+SAMPLE+STABILITY | Search INCURRED+SAMPLE+STABILITY |
| 10 | DELAYED RADIATION EFFECT | 1 | 50% | 0% | 1 | Search DELAYED+RADIATION+EFFECT | Search DELAYED+RADIATION+EFFECT |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LS 2616 | 74 | 84% | 17% | 41 |
| 2 | SYNTHETIC IMMUNOMODULATOR LINOMIDE | 37 | 74% | 11% | 28 |
| 3 | QUINOLINE 3 CARBOXAMIDE LINOMIDE | 20 | 66% | 8% | 19 |
| 4 | LINOMIDE | 18 | 53% | 9% | 23 |
| 5 | LS 2616 LINOMIDE | 17 | 100% | 3% | 8 |
| 6 | ORAL LAQUINIMOD | 15 | 82% | 4% | 9 |
| 7 | ABR 215062 | 15 | 77% | 4% | 10 |
| 8 | IMMUNOMODULATOR LINOMIDE | 10 | 61% | 4% | 11 |
| 9 | RAT PROSTATIC CANCERS | 9 | 67% | 3% | 8 |
| 10 | IMMUNOMODULATOR LS 2616 | 6 | 71% | 2% | 5 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis | 2011 | 9 | 14 | 64% |
| Efficacy and safety of laquinimod in multiple sclerosis: current status | 2013 | 3 | 22 | 77% |
| Oral laquinimod treatment in multiple sclerosis | 2011 | 6 | 16 | 56% |
| Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis | 2014 | 2 | 31 | 48% |
| Laquinimod in multiple sclerosis | 2012 | 10 | 12 | 67% |
| The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus | 2001 | 13 | 50 | 54% |
| Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer | 2014 | 3 | 46 | 30% |
| Mechanisms of action of tasquinimod on the tumour microenvironment | 2014 | 8 | 50 | 14% |
| Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system | 2001 | 6 | 59 | 66% |
| Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review) | 2013 | 0 | 20 | 65% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | GLOBAL INNOVAT RD | 5 | 63% | 2.0% | 5 |
| 2 | LUND | 2 | 22% | 2.4% | 6 |
| 3 | BONE MARROW TRANSPLANTAT CANC IMMUNOBIOL | 1 | 50% | 0.4% | 1 |
| 4 | BONE MARROW TRANSPLANTAT CANC IMMUNOTHER Y | 1 | 50% | 0.4% | 1 |
| 5 | UNIV HOSP TRANSPLANT SURG | 1 | 50% | 0.4% | 1 |
| 6 | UNIV HOSP MED MICROBIOL | 0 | 33% | 0.4% | 1 |
| 7 | ACT BIOTECH | 0 | 25% | 0.4% | 1 |
| 8 | PIOM EPHE | 0 | 25% | 0.4% | 1 |
| 9 | BMC D14 | 0 | 20% | 0.4% | 1 |
| 10 | NEUROANAT PEPTIDERG SYST 14 | 0 | 14% | 0.4% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000183745 | PEROPERATIVE BLEEDING//PRIMARY PROSTATE CULTURE//BLOOD VESSEL MORPHOLOGY |
| 2 | 0.0000124018 | SMON VIRUS//IMV//GRP STUDY EPIDEM NEUROPATHY |
| 3 | 0.0000108591 | GLATIRAMER ACETATE//INTERFERON BETA//INTERFERON BETA 1B |
| 4 | 0.0000096677 | ORGAN SYNTH GRP//4 HYDROXY 2 OXO 1 2 DIHYDROQUINOLINE 3 CARBOXAMIDES//4 HYDROXY 2 OXO 1 2 DIHYDROQUINOLINE 3 CARBOXYLIC ACIDS |
| 5 | 0.0000095405 | DEOXYSPERGUALIN//15 DEOXYSPERGUALIN//AXE IMMUNOL |
| 6 | 0.0000080554 | INO 2628 CZ//DOUBLE PEAKS//DISCONTINUOUS ABSORPTION |
| 7 | 0.0000063442 | EXPERIMENTAL AUTOIMMUNE NEURITIS//EXPERIMENTAL ALLERGIC NEURITIS//EXPERIMENTAL AUTOIMMUNE NEURITIS EAN |
| 8 | 0.0000060523 | LEFLUNOMIDE//DIHYDROOROTATE DEHYDROGENASE//DG RHEUMATOL |
| 9 | 0.0000060298 | MHC NONRESTRICTED CYTOTOXICITY//HISTAMINE DIHYDROCHLORIDE//BOWYER ONCOL |
| 10 | 0.0000057349 | TNP 470//METHIONINE AMINOPEPTIDASE//AGM 1470 |